An open-label, first-in-human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma.
Saved in:
| Title: | An open-label, first-in-human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma. |
|---|---|
| Authors: | Kapoor P; Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA., Nathwani N; Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, California, USA., Jelinek T; Department of Hematooncology, University Hospital Ostrava and University of Ostrava, Ostrava, Czech Republic., Pour L; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic., Perrot A; Department of Hematology, Institut Universitaire du Cancer de Toulouse, Toulouse, France., Dimopoulos MA; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece., Huang SY; Department of Hematology, National Taiwan University Hospital, Taipei, Taiwan., Spicka I; First Department of Medicine, Department of Hematology, First Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic., Chhabra S; Division of Hematology and Oncology, Department of Medicine, Mayo Clinic Arizona, Phoenix, Arizona, USA., Lichtman E; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.; Department of Medicine, Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Mateos MV; Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), University of Salamanca, Salamanca, Spain., Kanagavel D; Research and Development, Sanofi, Research and Development, Vitry-sur-Seine, France., Zhao L; Research and Development, Sanofi, Research and Development, Shanghai, China., Guillemin-Paveau H; Research and Development, Sanofi, Research and Development, Vitry-sur-Seine, France., Macé S; Research and Development, Sanofi, Research and Development, Vitry-sur-Seine, France., van de Velde H; Research and Development, Sanofi, Research and Development, Cambridge, Massachusetts, USA., Richardson PG; Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center, Boston, Massachusetts, USA. |
| Source: | European journal of haematology [Eur J Haematol] 2024 Nov; Vol. 113 (5), pp. 593-605. Date of Electronic Publication: 2024 Jul 12. |
| Publication Type: | Journal Article; Multicenter Study; Clinical Trial, Phase I |
| Journal Info: | Publisher: Blackwell Country of Publication: England NLM ID: 8703985 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0609 (Electronic) Linking ISSN: 09024441 NLM ISO Abbreviation: Eur J Haematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1600-0609 |
|---|---|
| DOI: | 10.1111/ejh.14270 |
